Difference between revisions of "Ibrutinib (Imbruvica)"
(Created page with "==General information== Class/mechanism: Irreversible inhibitor of Bruton's tyrosine kinase (BTK), which is an enzyme that participates in the B-cell receptor (BCR) signal cas...") |
m |
||
| Line 21: | Line 21: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:BTK inhibitors]] | ||
Revision as of 21:50, 9 January 2014
General information
Class/mechanism: Irreversible inhibitor of Bruton's tyrosine kinase (BTK), which is an enzyme that participates in the B-cell receptor (BCR) signal cascade. BCR signaling is believed to promote cell proliferation, adhesion, and survival in B-cell malignancies. Inhibition of BTK interferes with the processes above and may also have a downregulating immunomodulatory effect.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
Patient drug information
No information available.
History of changes in FDA indication
- 11/13/2013: Granted FDA accelerated approval for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Also known as
PCI-32765